Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Noninvasive screening by cell‐free DNA for 22q11.2 deletion: Benefits, limitations, and challenges

1 Jan 2019

Abstract excerpt

Cell-free DNA (cfDNA) testing for fetal aneuploidy is one of the most important technical advances in prenatal care. Additional chromosome targets beyond common aneuploidies, including the 22q11.2 microdeletion, are now available because of this clinical testing technology. While there are numerous potential benefits, 22q11.2 microdeletion screening using cfDNA testing also presents significant limitations and...

Topics

Join the communities discussing this publication.

Congenital heart defects research
Congenital Heart Disease Studies
Prenatal Screening and Diagnostics

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 30625249
DOI: 10.1002/pd.5391

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Noninvasive screening by cell‐free DNA for 22q11.2 deletion: Benefits, limitations, and challengesPMID 30625249Read ↗

The benefits and limitations of cell‐free DNA screening for 22q11.2 deletion syndromeSemantic proximity Read ↗

Current controversies in prenatal diagnosis 2: Cell‐free DNA prenatal screening should be used to identify all chromosome abnormalitiesSemantic proximity Read ↗

Cell-Free DNA ScreeningSemantic proximity Read ↗

Current Status of Testing for Microdeletion Syndromes and Rare Autosomal Trisomies Using Cell-Free DNA TechnologySemantic proximity Read ↗

Non-Invasive Prenatal Testing: Advances, Applications, and Limitations in Prenatal ScreeningSemantic proximity Read ↗

Non-Invasive Prenatal Testing: Current Perspectives and Future ChallengesSemantic proximity Read ↗

Clinical Perspective of Cell-Free DNA Testing for Fetal AneuploidiesSemantic proximity Read ↗

Advancements in Prenatal Genetic Screening and Testing: Emerging Technologies and Evolving ApplicationsSemantic proximity Read ↗

Advancements in Prenatal Genetics: Emerging Technologies and Evolving ApplicationsSemantic proximity Read ↗

Advances in Prenatal Cell‐Free DNA Screening for Dominant Monogenic Conditions: A Review of Current Progress and Future Directions in Clinical ImplementationSemantic proximity Read ↗

Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome.Semantic proximity Read ↗

PREIMPLANTATION GENETIC TESTING: Non-invasive prenatal testing for aneuploidy, copy-number variants and single-gene disordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.